Mostra i principali dati dell'item
Conformational properties of HIV-1 gp120/V3 immunogenic domains
dc.creator | Galanakis, P. A. | en |
dc.creator | Spyroulias, G. A. | en |
dc.creator | Rizos, A. | en |
dc.creator | Samolis, P. | en |
dc.creator | Krambovitis, E. | en |
dc.date.accessioned | 2015-11-23T10:26:52Z | |
dc.date.available | 2015-11-23T10:26:52Z | |
dc.date.issued | 2005 | |
dc.identifier | 10.2174/0929867054038982 | |
dc.identifier.issn | 9298673 | |
dc.identifier.uri | http://hdl.handle.net/11615/27619 | |
dc.description.abstract | Infection of target host cells by the human immunodeficiency virus-1 (HIV-1) is a multi-step process involving a series of conformational changes in the viral gp120 and gp41 proteins. Gp120 binding to the main cell receptor, CD4, on the surface of cells expressing this molecule, and interaction with the cell chemokine receptors CCR5 and CXCR4, are among the key events for HIV-1 infection. These steps are crucial for the virus and offer potential therapeutic targets. For this reason, understanding the structure and the physicochemical characteristics of the gp120 in relation to these interactions has drawn much attention. This review article focuses on the biologically important V3 region of the gp120 and summarizes the functional role, the sequence variation and the conformational features of V3 peptides, which are important for co-receptor selectivity, specificity and interaction. Synthetic V3 peptides have been extensively studied by NMR spectroscopy and X-ray crystallography, in solution or in solid state, in their free or bound form, and valuable information was generated with the aim to be exploited in the design of new, effective inhibitors of HIV-1 infection. The features of the potential gp120 interacting sites on the two chemokine co-receptors, CCR5 and CXCR4, are also discussed, and co-receptor blocking molecules under clinical trial are also reported. © 2005 Bentham Science Publishers Ltd. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-21044452929&partnerID=40&md5=a74f1ace8e5aafdf0142a779ea74bbff | |
dc.subject | AIDS | en |
dc.subject | CCR5/CXCR4 co-receptors | en |
dc.subject | HIV inhibitors | en |
dc.subject | HIV-1 gp120 | en |
dc.subject | V3 hypervariable loop | en |
dc.subject | X-ray crystallography and NMR spectroscopy | en |
dc.subject | 1,1' [1,4 phenylenebis(methylene)]bis(1,4,8,11 tetraazacyclotetradecane) | en |
dc.subject | 4,4' [carbonylbis[imino 1h pyrrole 4,2 diylcarbonylimino(1 methyl 1h pyrrole 4,2 diyl)carbonylimino]]bis(1,7 naphthalenesulfonic acid) | en |
dc.subject | alpha n acetylnona dextro arginine amide | en |
dc.subject | alx 40 | en |
dc.subject | antivirus agent | en |
dc.subject | CD4 antigen | en |
dc.subject | CD4 immunoglobulin G2 | en |
dc.subject | cell receptor | en |
dc.subject | chemokine receptor CCR5 | en |
dc.subject | chemokine receptor CXCR4 | en |
dc.subject | enfuvirtide | en |
dc.subject | glycoprotein gp 120 | en |
dc.subject | glycoprotein gp 41 | en |
dc.subject | maraviroc | en |
dc.subject | n [4 [[[6,7 dihydro 2 (4 methylphenyl) 5h benzocyclohepten 8 yl]carbonyl]amino]benzyl] n,n dimethyl 2h tetrahydropyran 4 aminium chloride | en |
dc.subject | t 1249 | en |
dc.subject | t 22 | en |
dc.subject | TNX 355 | en |
dc.subject | unclassified drug | en |
dc.subject | virus protein | en |
dc.subject | amino acid sequence | en |
dc.subject | cell surface | en |
dc.subject | cellular distribution | en |
dc.subject | clinical trial | en |
dc.subject | drug safety | en |
dc.subject | drug targeting | en |
dc.subject | human | en |
dc.subject | Human immunodeficiency virus 1 | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | immunogenetics | en |
dc.subject | nonhuman | en |
dc.subject | nuclear magnetic resonance spectroscopy | en |
dc.subject | protein binding | en |
dc.subject | protein conformation | en |
dc.subject | protein domain | en |
dc.subject | protein function | en |
dc.subject | protein localization | en |
dc.subject | protein motif | en |
dc.subject | protein protein interaction | en |
dc.subject | protein structure | en |
dc.subject | review | en |
dc.subject | solid state | en |
dc.subject | structure analysis | en |
dc.subject | X ray crystallography | en |
dc.subject | Anti-HIV Agents | en |
dc.subject | Chemokines | en |
dc.subject | Crystallography, X-Ray | en |
dc.subject | HIV Envelope Protein gp120 | en |
dc.subject | HIV Envelope Protein gp41 | en |
dc.subject | HIV Infections | en |
dc.subject | HIV-1 | en |
dc.subject | Humans | en |
dc.subject | Magnetic Resonance Spectroscopy | en |
dc.subject | Receptors, CCR5 | en |
dc.subject | Receptors, CXCR4 | en |
dc.title | Conformational properties of HIV-1 gp120/V3 immunogenic domains | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |